Skip to main content

Table 2 Results of area under the curve of CGM and glucose fluctuations at STEP 0 and at the end of this protocol

From: Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study

 

At the evaluation of STEP 0

At the end of this protocol

Results of continuous glucose monitoring

  

Number of patients

14

14

AUC for 24-h glycemic fluctuation (mg・h/dL)

4112.1

2986.3*

(3568.8-4338.5)

(2843.3-3504.0)

AUC for 4-h after breakfast glycemic fluctuation (mg・h/dL)

732.3

521.5*

(607.4-845.4)

(498.9-626.9)

AUC for 4-h after lunch glycemic fluctuation (mg・h/dL)

785.9

516.2*

(573.5-952.0)

(466.5-550.6)

AUC for 4-h after dinner glycemic fluctuation (mg・h/dL)

785.3

559.2*

(719.4-877.8)

(485.3-651.4)

AUC for 8-h from midnight to early morning glycemic fluctuation (00:00–08:00) (mg・h/dL)

1033.0

949.8

(911.4-1187.5)

(869.6-1074.3)

24-h mean glucose levels (mg/dL)

169.7

124.7*

(142.6-181.1)

(118.8-146.4)

SDs of 288 glucose levels for 24-h (mg/dL)

38.6

23.5*

(29.9-58.5)

(13.9-28.4)

Proportion of time (%) in hyperglycemia (>180 mg/dL)

40.7

7.9*

(17.4-53.7)

(0–17.2)

Proportion of time (%) in hypoglycemia (<70 mg/dL)

0

0

MAGE

91.1 (79.1-119.6)

61.3* (50.2-72.4)

Results of 7-point SMBG

  

Number of patients

16

16

M-value

28.8 (21.4-52.5)

8.7 *(5.0-15.7)

  1. Median (interquartile range)
  2. *P < 0.05
  3. CGM data were analyzed in a total of 14 patients because of missing CGM data in 2 of the 16 patients.